Yu Binbin, Li Rui, Zhu Xueqin, Chi Zhengbing
Department of Pediatric Dentistry, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, Shanghai, China.
National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.
Transl Cancer Res. 2023 Apr 28;12(4):784-792. doi: 10.21037/tcr-22-2704. Epub 2023 Apr 6.
This study aimed to investigate the influence of antibody CD166 on the inhibition of tumor and further investigate the influence on immune cells of tumor tissues in mice bearing oral squamous cell carcinoma (OSCC).
The xenograft model was established through subcutaneously injection of mouse OSCCs cells. Ten mice were randomly divided into two groups. The treatment group was treated with antibody CD166 and the control group was injected with the same volume normal saline. Hematoxylin and eosin (H&E) was used to confirm the tissue histopathology of xenograft mice model. Flow cytometry was used to detect the proportion of CD3CD8 T cells, CD8PD-1 cells and CD11bGr-1 myeloid-derived suppressor cells (MDSCs) cells in the tumor tissues.
After treatment with antibody CD166, the tumor volume and weight in xenograft mice model were significantly reduced. The result of flow cytometry showed that antibody CD166 showed no obvious influence on the proportion of CD3CD8 and CD8PD-1 T lymphocyte cells in the tumor tissues. In the antibody CD166 treatment group, the proportion of CD11bGr-1 MDSCs cells in tumor tissues was 1.930%±0.5317%, which was significantly lower than that of the control group, 4.940%±0.3252% (P=0.0013).
Antibody CD166 treatment helped reduce the proportion of CD11bGr-1 MDSCs cells, and produced obvious therapeutic effect on the treatment of mice bearing OSCC.
本研究旨在探讨抗体CD166对肿瘤抑制的影响，并进一步研究其对口腔鳞状细胞癌（OSCC）荷瘤小鼠肿瘤组织免疫细胞的影响。
通过皮下注射小鼠OSCC细胞建立异种移植模型。将10只小鼠随机分为两组。治疗组用抗体CD166治疗，对照组注射相同体积的生理盐水。苏木精和伊红（H&E）染色用于确认异种移植小鼠模型的组织病理学。流式细胞术用于检测肿瘤组织中CD3CD8 T细胞、CD8PD-1细胞和CD11bGr-1髓源性抑制细胞（MDSCs）的比例。
用抗体CD166治疗后，异种移植小鼠模型中的肿瘤体积和重量显著减小。流式细胞术结果显示，抗体CD166对肿瘤组织中CD3CD8和CD8PD-1 T淋巴细胞细胞的比例无明显影响。在抗体CD166治疗组中，肿瘤组织中CD11bGr-1 MDSCs细胞的比例为1.930%±0.5317%，显著低于对照组的4.940%±0.3252%（P=0.0013）。
抗体CD166治疗有助于降低CD11bGr-1 MDSCs细胞的比例，并对OSCC荷瘤小鼠的治疗产生明显的治疗效果。
